摘要
Abstract
Objective To investigate the clinical and fungal biomarker features of invasive pulmonary aspergillosis during at Beijing Chao-Yang Hospital,Capital Medical University from 2021 to 2023 and explore the predictive value of(1,3)-β-D-glu-can,serum galactomannan,and BALF GM tests for ICU admission in patients with microbiologic evidence.Methods Pa-tients diagnosed with IPA bypathologic and clinical criteria at Beijing Chao-Yang Hospital Affiliated to Capital Medical Uni-versity from January 2021 to December 2023 were enrolled.They were divided into COVID-19-positive and non-COVID-19 groups to compare different clinical characteristics and fungal markers between the two groups.ROC curves were used to de-termine optimal cut-off values for G test,serum GM,and BALF GM tests in predicting ICU admission,along with their sensitivity,specificity,positive predictive value,and negative predictive value.Results Significant differences were ob-served between COVID-19 and non-COVID-19 patients with IPA in age,interstitial lung disease,cardiac dysfunction,re-spiratory failure,and hypoalbuminemia(P＜0.05).Among patients with positive Aspergillus culture result,G test and serum GM test cut-off values of 13.74 and 0.27,showed specificities of 81.5％and 85.2％for predicting ICU admission re-spectively.BALF GM test at a cut-off of 1.22 demonstrated sensitivity and specificity of 72.7％and 74.1％,respectively.Conclusion COVID-19 patients with old age,interstitial lung disease,cardiac dysfunction,respiratory failure,or hypoalbu-minemia are more susceptible to COVID-19-associated pulmonary aspergillosis.BALF GM testing is an optimalindicator for predicting ICU admission in patients with microbiology evidence.关键词
新型冠状病毒/侵袭性肺曲霉病/(1,3)-β-D葡聚糖检测/GM试验Key words
COVID-19/invasive pulmonary aspergillosis/(1,3)-β-D-glucan test/GM test分类
医药卫生
